Regeneron (REGN) Gets a Hold Rating from Raymond James

In a report released today, Dane Leone from Raymond James maintained a Hold rating on Regeneron (REGNResearch Report). The company’s shares closed last Friday at $511.89.

According to, Leone is a 5-star analyst with an average return of 12.8% and a 60.3% success rate. Leone covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Adverum Biotechnologies, and Tarsus Pharmaceuticals.

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $635.13.

See today’s analyst top recommended stocks >>

The company has a one-year high of $664.64 and a one-year low of $441.00. Currently, Regeneron has an average volume of 822.2K.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.